| 血管免疫母细胞淋巴瘤的特点及治疗进展 |
| |
| 引用本文： | 张硕,刘爱春.血管免疫母细胞淋巴瘤的特点及治疗进展[J].现代肿瘤医学,2016,0(6):988-992. |
| |
| 作者姓名： | 张硕 刘爱春 |
| |
| 作者单位： | 哈尔滨医科大学附属肿瘤医院血液淋巴内科，黑龙江 哈尔滨 150081 |
| |
| 摘 要： | 血管免疫母细胞淋巴瘤是起源于T淋巴细胞的恶性肿瘤，具有独特的生物学、病理学及免疫表型，其治疗反应差，常规化疗后复发率高，目前尚无有效的治愈手段，预后较差，新药物的研发及造血干细胞移植得到了相对较好的治疗效果，给血管免疫母细胞淋巴瘤患者带来了生存机会，改善了预后。
|
| 关 键 词： | 血管免疫母细胞淋巴瘤 新药 治疗 |
Progress in the characteristics and treatment of angioimmunoblastic lymphoma |
| |
| Zhang Shuo,Liu Aichun.Progress in the characteristics and treatment of angioimmunoblastic lymphoma[J].Journal of Modern Oncology,2016,0(6):988-992. |
| |
| Authors: | Zhang Shuo Liu Aichun |
| |
| Institution: | Department of Hematology，Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China. |
| |
| Abstract: | Angioimmunoblastic lymphoma is originated from T cell malignant tumor,with poor response to treatment,conventional chemotherapy and the recurrence rate is high.There is currently no effective cure,prognosis is poor.The development of new drugs and hematopoietic stem cell transplantation has relatively good therapeutic effect. |
| |
| Keywords: | angioimmunoblastic lymphoma drug treatment |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
| 点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
